|
Sign In to gain access to subscriptions and/or personal tools.
|
The Tg rasH2 Mouse in Cancer Hazard Identification
Daniel Morton
Pharmacia Corporation, Skokie, IL, Dan.g.morton{at}pharmacia.com
Carl L. Alden
Millenium Pharmaceuticals, Boston, MA
Arthur J. Roth
Pharmacia Corporation, Skokie, IL
Toshimi Usui
Central Institute for Experimental Animals, Kawasaki, Japan
The Tg rasH2 transgenic mouse has been developed as an alternative to the lifetime mouse bioassay to predict the carcinogenic potential of chemicals. Unlike the p53+/- mouse, the Tg rasH2 mouse is sensitive to both genotoxic and nongenotoxic carcinogens. The Tg rasH2 mouse, officially designated CB6F1-TgN (RasH2), contains multiple copies of the human c-Ha-ras oncogene and promoter within its genome. These mice develop spontaneous and chemically induced neoplasms earlier in life and in greater numbers than wild-type mice, reflecting their enhanced sensitivity to neoplasia. The most common spontaneous neoplasms in control Tg rasH2 mice 8 to 9 months of age are lung adenomas and carcinomas (7.4% incidence), splenic hemangiomas and hemangiosarcoma s (5.4%), forestomach squamous cellpapillomas and carcinomas (2.4%), and skin neoplasms (1.2%). Simulations have demonstrated that 20 to 25 mice/sex/treatment group are required to provide the assay with adequate statistical power. Four of 6 known or suspected human carcinogens tested in Tg rasH2 mice were positive in this assay. For 19 nonmutagenic agents testing positive in conventional rodent bioassays, 7 chemicals were positive, 10 chemicals were negative, and 2 were equivocal. None of the 10 nonmutagenic rodent carcinogens that were negative in the Tg rasH2 mouse model are considered to be human carcinogens. All nonmutagenic chemicals that were negative in the conventional rodent bioassays were also negative in the Tg rasH2 model. Results for 15 of 18 mutagenic chemicals tested in Tg rasH2 mice agreed with the results of conventional rodent bioassays, and 3 results were equivocal. The Tg rasH2 mouse model appears to predict known or suspected human carcinogens as well as the traditional mouse bioassay, but with fewer positive results for nongenotoxic compounds that are not considered human carcinogens. The Tg rasH2 mouse model is the most thoroughly tested in vivo alternative to the lifetime mouse bioassay for nongenotoxic compounds administered by oral or parenteral routes. The U.S. FDA Carcinogenicity Assessment Committee has determined that the Tg rasH2 model has been adequately evaluated for consideration for carcinogenicity testing of pharmaceutical candidates and its use could contribute to the weight of evidence for carcinogenicity assessment. The FDA will consider proposals to replace lifetime mouse carcinogenicity studies with 6-month Tg rasH2 mouse studies to support pharmaceutical registration on a case-by-case basis.
Key Words: Bioassay • carcinogenicity • CB6F1-TgN (RasH2) • risk assessment • rodent • TgHras2 • transgenic.
References
- Anonymou s (1998). International Conference on Harmonization; Guidance on testing for carcinogenicity of pharmaceuticals. Fed Reg 63(35): 8983— 8986.
- Aoki T., Imai T., Ando T., Dodo T., Sagami F., Kerns WD, Usui T. ( 2000). Effects of clofibrate in the CB6F1-TG-RASH2 mouse. In: Workshop on the Evaluation of Alternative Methods for Carcinogenicity Testing. International Life Sciences Institute, Washington, DC.
- Contrera JF, DeGeorge J. (1998). In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals. Environ Health Perspect 106 (suppl 1): 71—80.[Web of Science][Medline]
[Order article via Infotrieve]
- De Jonghe S., Verbeeck J., Van Deun K., Brown M., Vynckier A., Vandenberghe J., Verstynen B., Lampo A., Monbaliu J., Jansen T., Coussement W. (2000). Results of 6-month oral carcinogenicity study with 17-β-estradiol in transgenic TgHras2 and wild-type mice. In: Workshop on the Evaluation of Alternative Methods for Carcinogenicity Testing. International Life Sciences Institute, Washington, DC.
- Maronpot RR, Mitsumori K., Mann P., Takaoka M., Yamamoto S., Usui T., Okamiya H., Nishikawa S., Nomura T. (2000). Interlaboratory comparison of the CB6F1-Tg rasH2 rapid carcinogenicity testing model. Toxicology 146: 149—159.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Mitsumori K., Koizumi H., Nomura T., Yamamoto S. (1998). Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies. Toxicol Pathol 26: 520—531.[Abstract/Free Full Text]
- Morton D., Dudek BR, Sagartz JE, Bunch RT, Curtiss SW, Kolaja KL, Wilker CE, Schlosser MJ, Alden CL (2000). Rapid-carcinogenicity testing of 1,4-dioxane, ethylene thiourea, cholestyramine, and sulfisoxasole using Tg-rasH2 mice. In: Workshop on the Evaluation of Alternative Methods for Carcinogenicity Testing. International Life Sciences Institute, Washington, DC.
- Mutai M., Sano F., Kusakabe M., Kobayashi K., Goto K., Sakairi T., Sugimoto J. (2000). Detection of carcinogenic potential of diethylstilbestrol and N-methyl-N-nitrosourea by the alternative testing model using Tg-rasH2 mouse. In: Workshop on the Evaluation of Alternative Methods for Carcinogenicity Testing. International Life Sciences Institute, Washington, DC.
- Nesfield SR, Allen JS, Klapwyk JC, Clarke CJ, Selinger K., Rickert DE (2000). Testing of clofibrate in a six-month gavage study using RasH2 mice. In: Workshop on the Evaluation of Alternative Methods for Carcinogenicity Testing. International Life Sciences Institute, Washington, DC.
- Rosenzweig BA, Curtiss SW, Sistare FD (2000). Assessment of transgene orientation in the Tg rasH2 transgenic mouse: A critical step in monitoring transgene stability of microinjected animals. In: Workshop on the Evaluation of Alternative Methods for Carcinogenicity Testing. International Life Sciences Institute, Washington, DC.
- Saitoh A., Kimura M., Takahashi R., Yokoyama M., Nomura T., Izawa M., Sekiya T., Nishimura S., Katsuki M. (1990). Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene 5: 1195—1200.[Web of Science][Medline]
[Order article via Infotrieve]
- Suemizu H., Ohnishi Y., Maruyama C., Tomisawa M., Muguruma K., Hioki K., Usui T., Kimura M., Tamaoki N., Nomura T. (2000). Molecular biological studies in the rasH2 transgenic mouse. In: Workshop on the Evaluation of Alternative Methods for Carcinogenicity Testing. International Life Sciences Institute, Washington, DC.
- Tanakamaru Z-Y., Kanno H., Ishimura Y., Kandori H., Yamasaki H., Nagayabu T., Kitazaki T., Sasaki S., Sakura Y., Mitani M., Nonoyama T. (2000). 26-week carcinogenicity study of metaproterenol sulfate in Tg-rasH2 mice. In: Workshop on the Evaluation of Alternative Methods for Carcinogenicity Testing. International Life Sciences Institute, Washington, DC.
- Tennant RW, Stasiewcz S., Mennear J., French JE, Spalding JW (1999). Genetically altered mouse models for identifying carcinogens. In: The Use of Short- and Medium-term Tests for Carcinogens and Data on Genetic Effects in Carcinogeni c Hazard Evaluation, McGregor DB, Rice JM, Venitt S (eds). IARC Scientific Publications No. 146, International Agency for Research on Cancer, Lyon, pp 123—150.
- Torii M., Itoh F., Ohno K., Kominami G., Hirano K., Tasaki T., Nara H. ( 2000). 26-week carcinogenicity study of sulfamethoxazol e in CB6F1-Tg-rasH2 mice. In: Workshop on the Evaluation of Alternative Methods for Carcinogenicity Testing. International Life Sciences Institute, Washington, DC.
- Toyosawa K., Okimoto K., Mise I., Kijima K., Tanaka K., Matsuoka N. (2000). Di(2-ethylhexyl) phthalate induces hepatocellular neoplasm in male rasH2 mice in 26-week carcinogenicity study. In: Workshop on the Evaluation of Alternative Methods for Carcinogenicity Testing. International Life Sciences Institute, Washington, DC.
- Tsuchiya T., Kobayashi K., Gotou K., Sugimoto J., Sano F., Usui T., Morohashi T., Mutai M. (2001). Spontaneous occurring skeletal myopathy in CB6F1-Tg rasH2 mice. Proceedings of the Society of Toxicologic Pathology Annual Meeting, Orlando FL.
- Ueda M., Kitayama E., Nakazawa M., Tamura H., Kajihara T., Uchimoto H. (2000). 26-week carcinogenicity study of phenobarbital in CB6F1-Tg rasH2 mice and examination of hepatic carcinogenicity of phenobarbital in CB6F1-Tg rasH2 mice initiated with N-diethylnitrosamine. In: Workshop on the Evaluation of Alternative Methods for Carcinogenicity Testing. International Life Sciences Institute, Washington, DC.
- Urano K., Yoshimura M., Suzuki S., Fukushima A., Kikuchi K., Usui T. ( 2000). Sequential histopathological study on Tg-rasH2 mice after administration of MNU. In: Workshop on the Evaluation of Alternative Methods for Carcinogenicity Testing. International Life Sciences Institute, Washington, DC.
- Yamamoto S., Hayashi Y., Mitsumori K., Nomura T. (1997). Rapid carcinogenicity testing system with transgenic mice harboring human prototype c-HRAS gene. Lab Animal Sci 47(2): 121—126.
- Yamamoto S., Mitsumori K., Kodama Y., Matsunuma H., Manabe S., Okamiya, H., Suzuki H., Fukudu T., Sakamaki Y., Sunaga M., Nomura G., Hioki K., Wakana S., Nomura T., Hayashi Y. (1996). Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harbouring human prototype C-Ha-ras gene than in control nontransgenic mice. Carcinogenesis 17: 2455—2461.[Abstract/Free Full Text]
- Yamamoto S., Urano K., Koizumi H., Wakana S., Hioki K., Mitsumori K., Kurokawa K., Hayashi Y., Nomura T. (1998). Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. Environ Health Perspect 106: 57—69.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
Toxicologic Pathology, Vol. 30, No. 1,
139-146 (2002)
DOI: 10.1080/01926230252824851
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Morton, K. L. Bailey, C. L. Stout, R. J. Weaver, K. A. White, M. J. Lorenzen, and D. J. Ball
N-Methyl-N-Nitrosourea (MNU): A Positive Control Chemical for p53+/- Mouse Carcinogenicity Studies
Toxicol Pathol,
December 1, 2008;
36(7):
926 - 931.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. G. Bridges, J. R. Selden, and S. Luo
Nonclinical Safety Profile of Telbivudine, a Novel Potent Antiviral Agent for Treatment of Hepatitis B
Antimicrob. Agents Chemother.,
July 1, 2008;
52(7):
2521 - 2528.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Miyamoto, Y. Yasui, M. Kim, S. Sugie, A. Murakami, R. Ishigamori-Suzuki, and T. Tanaka
A novel rasH2 mouse carcinogenesis model that is highly susceptible to 4-NQO-induced tongue and esophageal carcinogenesis is useful for preclinical chemoprevention studies
Carcinogenesis,
February 1, 2008;
29(2):
418 - 426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Lynch, J. Svoboda, S. Putta, H. E. J. Hofland, W. H. Chern, and L. A. Hansen
Mouse Skin Models for Carcinogenic Hazard Identification: Utilities and Challenges
Toxicol Pathol,
December 1, 2007;
35(7):
853 - 864.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Sellers, D. Mortan, B. Michael, N. Roome, J. K. Johnson, B. L. Yano, R. Perry, and K. Schafer
Society of Toxicologic Pathology Position Paper: Organ Weight Recommendations for Toxicology Studies
Toxicol Pathol,
August 1, 2007;
35(5):
751 - 755.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Okamura, M. Moto, M. Muguruma, T. Ito, M. Jin, Y. Kashida, and K. Mitsumori
A 26-Week Carcinogenicity Study of 2-Amino-3-Methylimidazo[4,5-f]Quinoline in rasH2 Mice
Toxicol Pathol,
February 1, 2006;
34(2):
199 - 205.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Morton, R. S. Sellers, S. M. Furst, K. D. Hawley, and J. R. May
Effect of Oral Gavage Dosing Regimens in Female Tg rasH2 Transgenic Mice
Toxicol Pathol,
June 1, 2004;
32(4):
413 - 417.
[Abstract]
[PDF]
|
|
|
|
|
